Ocular Therapeutix™ to Present at the Jefferies 2019 London Healthcare Conference
November 14 2019 - 8:00AM
Business Wire
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical
company focused on the formulation, development, and
commercialization of innovative therapies for diseases and
conditions of the eye, today announced that Donald Notman, Chief
Financial Officer of Ocular Therapeutix, will give a company
presentation on Thursday, November 21st at 8:40 a.m. GMT at the
Jefferies 2019 London Healthcare Conference being held at the
Waldorf Hilton in London, UK.
In addition to the presentation, the Company will host investor
meetings at the conference. Investors attending the conference who
are interested in meeting with Ocular Therapeutix management should
contact their Jefferies representative.
A live webcast of the presentation can be accessed by visiting
the Investors section of the Company’s website at
investors.ocutx.com. A replay of the webcast will be available on
the Company’s website for 90 days following the conclusion of the
event.
About Ocular Therapeutix, Inc. Ocular Therapeutix, Inc.
is a biopharmaceutical company focused on the formulation,
development, and commercialization of innovative therapies for
diseases and conditions of the eye using its proprietary
bioresorbable hydrogel-based formulation technology. Ocular
Therapeutix’s first commercial drug product, DEXTENZA®, is
FDA-approved for the treatment of ocular inflammation and pain
following ophthalmic surgery. Ocular Therapeutix has also begun a
Phase 3 clinical trial evaluating DEXTENZA for the treatment of
ocular itching associated with allergic conjunctivitis. OTX-TP
(intracanalicular travoprost insert) is an intracanalicular insert
in Phase 3 clinical development for the reduction of intraocular
pressure in patients with primary open-angle glaucoma and ocular
hypertension. The Company’s earlier stage assets include OTX-TIC,
an extended-delivery intracameral travoprost implant for the
reduction of intraocular pressure in patients with glaucoma and
ocular hypertension, as well as sustained release intravitreal
implants for the treatment of retinal diseases. These intravitreal
implants include OTX-TKI, containing a tyrosine kinase inhibitor
(TKI), and, in collaboration with Regeneron, OTX-IVT, an
extended-delivery protein-based anti-vascular endothelial growth
factor (VEGF) trap. Ocular Therapeutix's first product, ReSure®
Sealant, is FDA-approved to seal corneal incisions following
cataract surgery.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191114005159/en/
Investors Ocular Therapeutix Donald Notman Chief
Financial Officer dnotman@ocutx.com or Westwicke, an ICR Company
Chris Brinzey, 339-970-2843 chris.brinzey@westwicke.com
Media Ocular Therapeutix Scott Corning Senior Vice
President, Commercial scorning@ocutx.com
Ocular Therapeutix (NASDAQ:OCUL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ocular Therapeutix (NASDAQ:OCUL)
Historical Stock Chart
From Sep 2023 to Sep 2024